Five-Week, Multi-center, Phase I Clinical Trial to Evaluate Safety of Homeo-GH After Intra Venus Administration for the Treatment of Graft Versus Host Disease Patients
Trial Snapshot
- Phase
- Phase 1
- Status
- Completed
- Sponsor
- HomeoTherapy Co., Ltd
- Enrollment
- 10
- Locations
- 8
- Primary Endpoint
- To evaluate number of paticipants with adverse events
Study Overview
Brief Summary
Official Title: Five-Week, Multi-center, Phase I Clinical Trial to Evaluate Safety of Homeo-GH after Intra Venus Administration for the Treatment of Graft versus Host Disease Patients
Sponsor: HomeoTherapy Co.,Ltd
Study Design: Single Group, Open Label, 5 Week, Safety Study
This study is designed to evaluate the safety of ex-vivo cultured adult human clonal mesenchymal stem cells (cMSC) derived from human bone marrow in subjects experiencing acute or chronic graft-versus-host disease (GVHD).
Study Type: Interventional
Detailed Description
Allogeneic MSCs being used in current human clinical trials are nonclonal, i.e., such MSCs may have other types of cells in the final stem cell product. Some concerns exist about the heterogeneity of these nonclonal MSCs that are isolated and expanded by the conventional density-gradient centrifugation method. Recently, we developed a new protocol, called the subfractionation culturing method (SCM), to generate single-cell-derived clonal MSC (cMSC) lines from whole bone marrow aspirate without employing any centrifugation step for mononuclear cells and enzyme treatment process. This method allowed us to rapidly establish single-cell-derived human clonal MSC (hcMSC) lines from raw bone marrow aspirates and to establish a library of these hcMSC lines (Song et al., 2008).
The goal of this study is to evaluate the safety of allogeneic cMSCs established by the SCM and manufactured in GMP facility. This phase I clinical trial is a multicenter, single dose study of cMSC (1 x 10e6 cMSCs/Kg recipient's bodyweight). Clonal MSCs will be infused to acute or chronic GVHD patients via an intravenous injection. Every patients will receive the same treatment
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Informed consent obtained from patient
- •Patients with ages greater than 18 years
- •Neutrophill count > 1,000 cells/mm3
- •Adequated cardiac function with no evidence of cardiac disease
- •Patients who had complete remission after bone marrow transplantation
- •Patients who can sign an informed consent form by him- or her-self or legal representative
Exclusion Criteria
- •Patients with unstable transplant after bone marrow transplantation
- •Patients with unstable vital sign
- •Patients with positive penicillin skin test
- •Patients who had transplantation to treat solid tumor
- •Patients with bacterial, viral or fungal infection not being controlled by the adequate treatment (more than moderate infection)
- •Patients who, in the investigator's point of view, are not in proper state for the treatment
Outcomes
Primary Outcomes
To evaluate number of paticipants with adverse events
Time Frame: Within the first 5 week
Aderse Events were record relationship with Investigational Product * Not related * Unlikely * Possible * Probable * High probable The severity of adverse events were graded refer to CTCAE (Common Terminology Criteria for Adverse Events) Ver.4.0
Secondary Outcomes
- GVHD clinical response(Within the first 5 week)